BONIVA INJECTION Rx
Generic Name and Formulations:
Ibandronate (as sodium) 3mg/3mL; soln for IV inj.
Indications for BONIVA INJECTION:
Prevention and treatment of postmenopausal osteoporosis.
Limitations Of use:
Optimal duration of use has not been determined. For patients at low-risk for fracture: consider drug discontinuation after 3–5yrs.
Must be given by healthcare professional. Give as IV bolus inj over 15–30secs. 3mg every 3 months; if dose is missed, give as soon as possible, then every 3 months from the date of last inj.
Hypocalcemia. Tabs: Esophagus abnormalities which delay esophageal emptying (eg, stricture, achalasia). Inability to stand or sit upright for at least 60mins.
Active upper GI disease; discontinue and reevaluate if signs/symptoms of esophageal reaction occur. Severe renal impairment (CrCl <30mL/min): not recommended. Correct preexisting hypocalcemia, other mineral or bone disturbances before starting. Risk of osteonecrosis of the jaw; consider discontinuing therapy during invasive dental procedures (eg, tooth extraction, implants, surgery). History of bisphosphonate exposure: evaluate for atypical fractures if thigh/groin pain develops; consider withholding therapy until risk/benefit assessment. Ensure adequate Vit. D and calcium intake. Reevaluate periodically. Inj: check renal function before each dose. Pregnancy. Nursing mothers.
Calcium, aluminum, magnesium, other multivalent cations reduce absorption (separate dosing by at least 60mins). Caution with aspirin, NSAIDs, other GI irritants. May interfere with bone-imaging agents. Inj: concomitant nephrotoxic agents; monitor for renal toxicity.
Back pain, dyspepsia, pain in extremity, diarrhea, headache, myalgia; musculoskeletal pain (discontinue if severe), esophagitis, esophageal or gastric ulcer, jaw osteonecrosis, atypical femur fractures. Inj: inj site reactions, flu-like syndrome, anaphylaxis.
Blister pack—3; Kit—1 (prefilled syringe + supplies)
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
- Anticancer Properties of The Probiotic Kefir: A Review
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
- Daily Aspirin Reduced Risk of HBV-Related Hepatocellular Carcinoma
- Lanreotide Effectively Controls Diarrhea, Flushing in Neuroendocrine Tumors
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|